CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025 ...

Wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Danish drugmaker Novo Nordisk has launched its popular weight-loss drug Wegovy in India, months after its rival Mounjaro’s ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Infection, delayed kidney function, kidney loss and death are all risks associated with kidney transplant surgery in obese ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...